- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 277/40 - Radicaux amino ou imino non substitués
Détention brevets de la classe C07D 277/40
Brevets de cette classe: 138
Historique des publications depuis 10 ans
|
11
|
11
|
8
|
5
|
5
|
8
|
10
|
3
|
6
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Aldeyra Therapeutics, Inc. | 110 |
11 |
| Bayer Cropscience AG | 2014 |
5 |
| Oryzon Genomics S.A. | 109 |
5 |
| Allergan, Inc. | 2337 |
4 |
| Duke University | 3090 |
4 |
| The University of North Carolina at Chapel Hill | 2057 |
4 |
| The Board of Regents of the University of Texas System | 2220 |
4 |
| Immunesensor Therapeutics, Inc. | 35 |
4 |
| The Regents of the University of California | 20108 |
3 |
| City of Hope | 997 |
3 |
| Medivir AB | 123 |
3 |
| Vivoryon Therapeutics N.V. | 44 |
3 |
| Bayer Intellectual Property GmbH | 2487 |
2 |
| The Board of Trustees of the Leland Stanford Junior University | 6476 |
2 |
| Arcus Biosciences, Inc. | 140 |
2 |
| Atrogi AB | 55 |
2 |
| Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | 825 |
2 |
| Egis Gyogyszergyar Rt. | 54 |
2 |
| Obschestvo S Ogranichennoi Otvetsttvennoctiyu "bionika" | 2 |
2 |
| Ranbaxy Laboratories Limited | 292 |
2 |
| Autres propriétaires | 69 |